Who is sponsoring NCT07264127?

NCT07264127 is sponsored by Tabark H. Omran.

What drugs are being tested in NCT07264127?

Interventions in NCT07264127: The use of 0.016×0.014 copper nickel titanium arch wire during the alignment stage., Use of 0.014- then 0.016-inch heat-activated nickel titanium arch wire during the alignment stage..

What condition does NCT07264127 study?

NCT07264127 studies Effectiveness of the I-arch System.

Is NCT07264127 still recruiting?

NCT07264127 is currently recruiting now. Last updated 17 April 2026.

Last reviewed 2026-04-17 · How we verify

NCT07264127

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

I-arch in Action: Early Clinical Impact From a Randomized Controlled Trial

Recruiting now NA Last updated 17 April 2026

What this trial tests

NA trial testing The use of 0.016×0.014 copper nickel titanium arch wire during the alignment stage. in Effectiveness of the I-arch System in 34 participants. Currently enrolling.

Timeline

1 December 2025

Primary endpoint
1 July 2026

1 September 2026

Quick facts

Lead sponsor	Tabark H. Omran
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	34
Start date	1 December 2025
Primary completion	1 July 2026
Estimated completion	1 September 2026
Sites	1 location across Iraq

Drugs / interventions tested

The use of 0.016×0.014 copper nickel titanium arch wire during the alignment stage.
Use of 0.014- then 0.016-inch heat-activated nickel titanium arch wire during the alignment stage.

Conditions studied

Effectiveness of the I-arch System — all drugs for Effectiveness of the I-arch System →

Sponsor

Tabark H. Omran

Who can join

12 and older, any sex, with Effectiveness of the I-arch System. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The rate of alignment
Time frame: 16 weeks
Alignment rate will be measured using Little's Irregularity Index on digital dental models. This index range between 0 to 10. "0" indicates perfect alignment, while "10" indicates very severe irregularities.

Sponsor's own description

The goal of this clinical trial is to learn if the I-arch system works to align the moderately misaligned teeth in patients seeking orthodontic treatment. it aims to answer the following questions: * Does I-arch system increase the rate of teeth alignment? * Does I-arch system produce significant changes in arch width and incisors inclination? * Does I-arch system decrease the intensity of patient-reported pain and root resorption? Researchers will compare the effectiveness of the I-arch and MBT arch wire system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07264127 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tabark H. Omran
Last refreshed: 17 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07264127.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing